Search Medical Condition
Please enter condition
Please choose location

Manchester, Connecticut Clinical Trials

A listing of Manchester, Connecticut clinical trials actively recruiting patient volunteers.

RESULTS

Found (91) clinical trials

Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension

This is a multi-site, placebo-controlled, double-blind, randomized withdrawal, time to intervention study with a duration of up to 36 weeks, consisting of 5 periods: Screening Period: up to 4 weeks duration; Open-Label Titration Period (Titration Period): up to 4 weeks duration; Open-Label Treatment Period (Open-Label Period): 12 weeks duration; Double-Blind ...

Phase

1.29 miles

Learn More »

Connect MDS/AML Disease Registry

This Disease Registry will collect data on patient characteristics, treatment patterns and clinical outcomes. The objective is to describe how newly diagnosed MDS, ICUS or AML patients are treated; and to build a knowledge base regarding the effectiveness and safety of front-line and subsequent treatment regimens in both community and ...

Phase N/A

1.29 miles

Learn More »

A Study to Assess the Efficacy and Safety of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients

A multi-center, global, randomized, double-blind, double-dummy, active-controlled, parallel-group study in adult subjects with fluctuating PD. The study will have 2 open label Titration periods of 6 weeks each prior to the double blind Maintenance period. In the open label periods all patients will be stabilized on the active comparator Sinemet® ...

Phase

3.67 miles

Learn More »

Efficacy Safety and Tolerability of Multiple Dosing Regimens of Oral AGN-241689 in Episodic Migraine Prevention

This study will evaluate the safety and tolerability of the following doses of AGN-241689: 10 mg once daily (QD), 30 mg QD, 30 mg twice daily (BID), 60 mg QD, and 60 mg BID for the prevention of episodic migraine and will characterize the dose/response relationship.

Phase

4.45 miles

Learn More »

Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention

A Phase 2a, randomized, double-blind, placebo-controlled, 3-arm parallel group study to evaluate the efficacy and safety of AMG 301 in subjects with chronic migraine or episodic migraine.

Phase

4.45 miles

Learn More »

Safety Follow-up Study in Subjects With Silicone Gel-filled Breast Implants as Compared Both to Saline-filled Breast Implants and to National Norms

Ten year safety study examining rates of rare adverse events, child bearing issues, effects of mammography, MRI compliance and results, and long-term benefit of silicone-filled breast implants.

Phase N/A

5.24 miles

Learn More »

Migraine Treatment With Nerivio Migra Neurostimulation Device

This is a prospective, randomized, double-blind, sham controlled multi-center trial. Ratio between treatment and control groups will be 1:1, stratified by center and use of preventive medications.

Phase N/A

7.8 miles

Learn More »

Safety Tolerability & Efficacy on LDL-C of Evolocumab in Subjects With HIV & Hyperlipidemia/Mixed Dyslipidemia

LDL-C = low density lipoprotein cholesterol QM = once monthly Double blind = neither the subject, the site staff nor the Sponsor study team will know whether the subject is receiving either evolocumab or placebo Open label = all subjects receive evolocumab

Phase

8.31 miles

Learn More »

The Circulating Cell-free Genome Atlas Study

This is a prospective, multi-center, observational study with collection of de-identified biospecimens and clinical data from at least 10,000 participants from clinical networks in the United States. The study will enroll at least 7000 cancer subjects with multiple solid tumor types (the CANCER arm) and at least 3000 representative subjects ...

Phase N/A

8.31 miles

Learn More »

Study Of Gemcitabine Nab-paclitaxel PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma

The purpose of this study is to test any good and bad effects of the study drug called PEGPH20. PEGPH20 alone is considered investigational. The Food and Drug Administration (FDA) has not approved the marketing or sale of PEGPH20, but have authorized its use in research studies with humans. PEGPH20 ...

Phase N/A

8.31 miles

Learn More »